marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2023-Q1
added 05-08-2023
ACADIA Pharmaceuticals Balance Sheet 2011-2024 | ACAD
Annual Balance Sheet ACADIA Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-83 M | -276 M | -180 M | -135 M | -69.4 M | -164 M | -102 M | -61.9 M | -11.7 M | -57.9 M | -6.86 M |
Long Term Debt |
56.1 M | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
8.3 M | 5.09 M | 3.43 M | - | - | - | - | - | - | - | 32 K |
Total Non Current Liabilities |
- | 49.6 M | 9.22 M | 1.56 M | 191 K | 157 K | 232 K | 135 K | 8 K | 17.7 M | 2.59 M |
Total Current Liabilities |
96.1 M | 106 M | 74.8 M | 59.6 M | 49 M | 42.6 M | 21.9 M | 15.8 M | 6.98 M | 5.95 M | 6.16 M |
Total Liabilities |
159 M | 156 M | 84 M | 61.1 M | 49.2 M | 42.7 M | 22.1 M | 16 M | 6.99 M | 23.6 M | 8.75 M |
Deferred Revenue |
- | - | - | - | - | 2.64 M | - | - | 55 K | 434 K | 669 K |
Retained Earnings |
-2.15 B | -1.99 B | -1.7 B | -1.47 B | -1.22 B | -934 M | -663 M | -498 M | -406 M | -368 M | -347 M |
Total Assets |
700 M | 783 M | 783 M | 540 M | 385 M | 561 M | 222 M | 325 M | 189 M | 109 M | 32.1 M |
Cash and Cash Equivalents |
147 M | 326 M | 190 M | 135 M | 69.4 M | 164 M | 102 M | 61.9 M | 11.7 M | 57.9 M | 6.89 M |
Book Value |
541 M | 627 M | 699 M | 479 M | 335 M | 518 M | 200 M | 309 M | 182 M | 85 M | 23.4 M |
Total Shareholders Equity |
541 M | 627 M | 699 M | 479 M | 335 M | 518 M | 200 M | 309 M | 182 M | 85 M | 23.4 M |
All numbers in USD currency
Quarterly Balance Sheet ACADIA Pharmaceuticals
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
51.4 M | 52.7 M | - | 54.7 M | 55.5 M | 56.1 M | 57.7 M | 59.1 M | 60.6 M | 44.5 M | 44.5 M | 44.5 M | 44.5 M | 6.36 M | 6.36 M | 6.36 M | 6.36 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.56 M | 1.21 M | 1.03 M | 782 K | 191 K | 191 K | 191 K | 191 K | 157 K | 157 K | 157 K | 157 K | 232 K | 232 K | 232 K | 232 K | 135 K | 135 K | 135 K | 135 K | 8 K | 8 K | 8 K | 8 K | - | - | - | - | - | - | - | - |
Total Liabilities |
281 M | 187 M | - | 178 M | 179 M | 159 M | 151 M | 160 M | 174 M | 156 M | 156 M | 156 M | 156 M | 84 M | 84 M | 84 M | 84 M | 61.1 M | 61.1 M | 61.1 M | 61.1 M | 49.2 M | 49.2 M | 49.2 M | 49.2 M | 42.7 M | 42.7 M | 42.7 M | 42.7 M | 22.1 M | 22.1 M | 22.1 M | 22.1 M | 16 M | 16 M | 16 M | 16 M | 6.99 M | 6.99 M | 6.99 M | 6.99 M | 5.95 M | 5.95 M | 9.17 M | 8.93 M | 8.75 M | 8.75 M | 8.75 M | 8.75 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.13 M | 2.64 M | 2.64 M | 2.64 M | 2.64 M | - | - | - | - | - | 15 K | 29 K | 42 K | 55 K | 55 K | 55 K | 55 K | 434 K | 434 K | 434 K | 434 K | 669 K | 669 K | 669 K | 669 K |
Retained Earnings |
-2.41 B | -2.37 B | - | -2.3 B | -2.27 B | -2.15 B | -2.11 B | -2.1 B | -2.05 B | -1.99 B | -1.99 B | -1.99 B | -1.99 B | -1.7 B | -1.7 B | -1.7 B | -1.7 B | -1.47 B | -1.47 B | -1.47 B | -1.47 B | -1.22 B | -1.22 B | -1.22 B | -1.22 B | -934 M | -934 M | -934 M | -934 M | -663 M | -663 M | -663 M | -663 M | -498 M | -498 M | -498 M | -498 M | -406 M | -406 M | -406 M | -406 M | -368 M | -368 M | -368 M | -368 M | -347 M | -347 M | -347 M | -347 M |
Total Assets |
655 M | 588 M | - | 613 M | 624 M | 700 M | 718 M | 724 M | 755 M | 783 M | 783 M | 783 M | 783 M | 783 M | 783 M | 783 M | 783 M | 540 M | 540 M | 540 M | 540 M | 385 M | 385 M | 385 M | 385 M | 561 M | 561 M | 561 M | 561 M | 222 M | 222 M | 222 M | 222 M | 325 M | 325 M | 325 M | 325 M | 189 M | 189 M | 189 M | 189 M | 109 M | 109 M | 109 M | 109 M | 32.1 M | 32.1 M | 32.1 M | 32.1 M |
Cash and Cash Equivalents |
291 M | 115 M | - | 140 M | 205 M | 147 M | 94.6 M | 267 M | 304 M | 326 M | 326 M | 326 M | 326 M | 190 M | 190 M | 190 M | 190 M | 135 M | 135 M | 135 M | 135 M | 69.4 M | 69.4 M | 69.4 M | 69.4 M | 164 M | 164 M | 164 M | 164 M | 102 M | 102 M | 102 M | 102 M | 61.9 M | 61.9 M | 61.9 M | 61.9 M | 11.7 M | 11.7 M | 11.7 M | 11.7 M | 57.9 M | 57.9 M | 57.9 M | 57.9 M | 6.89 M | 6.89 M | 6.89 M | 6.89 M |
Book Value |
374 M | 400 M | - | 435 M | 445 M | 541 M | 567 M | 565 M | 582 M | 627 M | 627 M | 627 M | 627 M | 699 M | 699 M | 699 M | 699 M | 479 M | 479 M | 479 M | 479 M | 335 M | 335 M | 335 M | 335 M | 518 M | 518 M | 518 M | 518 M | 200 M | 200 M | 200 M | 200 M | 309 M | 309 M | 309 M | 309 M | 182 M | 182 M | 182 M | 182 M | 103 M | 103 M | 99.4 M | 99.7 M | 23.4 M | 23.4 M | 23.4 M | 23.4 M |
Total Shareholders Equity |
374 M | 400 M | - | 435 M | 445 M | 541 M | 567 M | 565 M | 582 M | 627 M | 627 M | 627 M | 627 M | 699 M | 699 M | 699 M | 699 M | 479 M | 479 M | 479 M | 479 M | 335 M | 335 M | 335 M | 335 M | 518 M | 518 M | 518 M | 518 M | 200 M | 200 M | 200 M | 200 M | 309 M | 309 M | 309 M | 309 M | 182 M | 182 M | 182 M | 182 M | 85 M | 85 M | 85 M | 85 M | 23.4 M | 23.4 M | 23.4 M | 23.4 M |
All numbers in USD currency